KALA BIO, Inc. announces it has entered into securities purchase agreement with certain institutional investors to issue 10,901Series G Convertible Non-Redeemable Preferred Shares at a issue price of $788.90 per preferred share for gross proceeds of $8,599,798.9 on March 25, 2024. The transaction is expected to close on March 26, 2024. The transaction will include participation from 667, L.P. for 1,075 Preferred Shares and Baker brothers life sciences, L.P for 9,826 Preferred Shares.